REGISTERED
on 27 Aug 2024
Last Applicant/ Owned by
Surrey Research Park GUILDFORD, Surrey GU2 7RE
GB
Serial Number
79358923 filed on 13th May 2022
Registration Number
7483832 registered on 27th Aug 2024
Correspondent Address
Evi T. Christou
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
COLHYSILIC
Nanoparticle substances and nanoparticles for use in industry, science and research, namely, silicon; silicon for use in industry, science and research; silicon nanoparticle materials for use in industry, science and research; porous silicon nanoparticle materials for use in industry, science and research; lipid nanoparticles for use in industry, science and research; silicon-lipid nanoparticles f Read More
Classification Information
Class [005]
Pharmaceutical Products
Nanoparticle-based pharmaceutical substances and nanoparticle-based pharmaceutical preparations for medical, veterinary and pharmaceutical purposes namely drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle substances and silicon nanoparticle preparations for medical, veterinary and pharmaceutical purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines, porous silicon nanoparticle substances and porous silicon nanoparticle preparations for medical, veterinary and pharmaceutical purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticle substances and lipid nanoparticle preparations for medical, veterinary and pharmaceutical purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticle substances and silicon-lipid nanoparticle preparations for medical, veterinary and pharmaceutical purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for medical, veterinary and pharmaceutical purposes, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for medical, veterinary and pharmaceutical purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for medical, veterinary and pharmaceutical purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle substances and nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle substances and silicon nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle substances and porous silicon nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticle substances and lipid nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticle substances and silicon-lipid nanoparticle preparations for pharmaceutical, medical and veterinary diagnosis purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for pharmaceutical, medical and veterinary diagnosis purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for pharmaceutical, medical and veterinary diagnosis purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for pharmaceutical, medical and veterinary diagnosis purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; nanoparticle substances and nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon nanoparticle substances and silicon nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; porous silicon nanoparticle substances and porous silicon nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticle substances and lipid nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticle substances and lipid nanoparticle preparations for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles for medical, veterinary and pharmaceutical treatment purposes, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; drug delivery agents, namely, pharmaceutical nanoparticle preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances ; drug delivery agents, namely, pharmaceutical silicon nanoparticle preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; drug delivery agents, namely, pharmaceutical porous silicon nanoparticle preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; drug delivery agents, namely, lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; drug delivery agents, namely, silicon-lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; drug delivery agents, namely, silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; drug delivery agents, namely, silicon-stabilised lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; drug delivery agents, namely, stabilised lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; pharmaceutical nanoparticle preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; pharmaceutical silicon nanoparticle preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; pharmaceutical porous silicon nanoparticle preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising of chemical, biochemical, biological and pharmaceutical substances, namely, drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicines, vaccines, medical treatments, veterinary medicines, veterinary treatments, and veterinary vaccines; pharmaceutical preparations for stabilising nucleic acids; pharmaceutical nanoparticle preparations for stabilising nucleic acids; pharmaceutical silicon nanoparticle preparations for stabilising nucleic acids; pharmaceutical porous silicon nanoparticle preparations for stabilising nucleic acids; lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; pharmaceutical preparations for stabilising nucleic acid-lipid complexes; pharmaceutical nanoparticle preparations for stabilising nucleic acid-lipid complexes; pharmaceutical silicon nanoparticle preparations for stabilising nucleic acid-lipid complexes; pharmaceutical porous silicon nanoparticle preparations for stabilising nucleic acid-lipid complexes; lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid- lipid complexes; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical nanoparticle preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical silicon nanoparticle preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical porous silicon nanoparticle preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; lipid nanoparticle materials being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; silicon-lipid nanoparticle materials being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemical, biochemical, biological and pharmaceutical substances; pharmaceutical preparations for controlled release and transfection of nucleic acids; pharmaceutical nanoparticle preparations for controlled release and transfection of nucleic acids; pharmaceutical silicon nanoparticle preparations for controlled release and transfection of nucleic acids; pharmaceutical porous silicon nanoparticle preparations for controlled release and transfection of nucleic acids; lipid nanoparticle materials being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-lipid nanoparticle materials being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids; stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [001]
Chemical Products
Nanoparticle substances and nanoparticles for use in industry, science and research, namely, silicon; silicon for use in industry, science and research; silicon nanoparticle materials for use in industry, science and research; porous silicon nanoparticle materials for use in industry, science and research; lipid nanoparticles for use in industry, science and research; silicon-lipid nanoparticles for use in industry, science and research; silicon-stabilised hybrid lipid nanoparticles for use in industry, science and research; silicon-stabilised lipid nanoparticles for use in industry, science and research; stabilised lipid nanoparticles for use in industry, science and research; chemical materials, namely, silicon for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; chemical materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; silicon-lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals; chemical materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon-lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; chemical materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; porous silicon nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; silicon-lipid nanoparticle materials for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; silicon-stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; stabilised lipid nanoparticles for carrying and delivery of chemical, biochemical and biological substances for use in the manufacture of vaccines; chemical materials for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon nanoparticle materials for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; porous silicon nanoparticle materials for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; lipid nanoparticle materials for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-lipid nanoparticle materials for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-stabilised lipid nanoparticles for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; stabilised lipid nanoparticles for stabilising of chemical, biochemical and biological substances for use in the manufacture of pharmaceuticals, cosmetics and chemicals; chemical materials for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; porous silicon nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; lipid nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-lipid nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-stabilised lipid nanoparticles for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; stabilised lipid nanoparticles for stabilising nucleic acids for use in the manufacture of pharmaceuticals, cosmetics and chemicals; chemical materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon nanoparticle materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals; porous silicon nanoparticle materials for stabilising of nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals; lipid nanoparticle materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-lipid nanoparticle materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals; silicon- stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals; stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticals, cosmetics and chemicals
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 79358923
Mark Type
No Service/Collective Mark
Attorney Docket Number
No 008814.00014
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
Yes
66A Current
Yes
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 27th Nov 2024 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| 27th Aug 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 27th Aug 2024 | REGISTERED-PRINCIPAL REGISTER |
| 30th Jun 2024 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| 11th Jun 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 11th Jun 2024 | PUBLISHED FOR OPPOSITION |
| 07th Jun 2024 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| 07th Jun 2024 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| 22nd May 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 09th May 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |